Paragon Biosciences LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Paragon Biosciences LLC
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Some believe unmet need refers only to rare diseases and tiny patient populations. But it is more than this. In 2020, the term sits at the heart of decision-making for drug makers – along with cost, access and value, of course.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.